These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 20623514

  • 1. The ASPP interaction network: electrostatic differentiation between pro- and anti-apoptotic proteins.
    Benyamini H, Friedler A.
    J Mol Recognit; 2011; 24(2):266-74. PubMed ID: 20623514
    [Abstract] [Full Text] [Related]

  • 2. A model for the interaction between NF-kappa-B and ASPP2 suggests an I-kappa-B-like binding mechanism.
    Benyamini H, Leonov H, Rotem S, Katz C, Arkin IT, Friedler A.
    Proteins; 2009 Nov 15; 77(3):602-11. PubMed ID: 19507243
    [Abstract] [Full Text] [Related]

  • 3. Regulation of ASPP2 interaction with p53 core domain by an intramolecular autoinhibitory mechanism.
    Rotem-Bamberger S, Katz C, Friedler A.
    PLoS One; 2013 Nov 15; 8(3):e58470. PubMed ID: 23472201
    [Abstract] [Full Text] [Related]

  • 4. Insights into the structure and protein-protein interactions of the pro-apoptotic protein ASPP2.
    Rotem S, Katz C, Friedler A.
    Biochem Soc Trans; 2007 Nov 15; 35(Pt 5):966-9. PubMed ID: 17956256
    [Abstract] [Full Text] [Related]

  • 5. Molecular mechanisms underlying the interaction of protein phosphatase-1c with ASPP proteins.
    Skene-Arnold TD, Luu HA, Uhrig RG, De Wever V, Nimick M, Maynes J, Fong A, James MN, Trinkle-Mulcahy L, Moorhead GB, Holmes CF.
    Biochem J; 2013 Feb 01; 449(3):649-59. PubMed ID: 23088536
    [Abstract] [Full Text] [Related]

  • 6. The structure and interactions of the proline-rich domain of ASPP2.
    Rotem S, Katz C, Benyamini H, Lebendiker M, Veprintsev D, Rüdiger S, Danieli T, Friedler A.
    J Biol Chem; 2008 Jul 04; 283(27):18990-9. PubMed ID: 18448430
    [Abstract] [Full Text] [Related]

  • 7. Highly homologous proteins exert opposite biological activities by using different interaction interfaces.
    Amir AI, van Rosmalen M, Mayer G, Lebendiker M, Danieli T, Friedler A.
    Sci Rep; 2015 Jul 01; 5():11629. PubMed ID: 26130271
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Factor inhibiting HIF-1 (FIH-1) modulates protein interactions of apoptosis-stimulating p53 binding protein 2 (ASPP2).
    Janke K, Brockmeier U, Kuhlmann K, Eisenacher M, Nolde J, Meyer HE, Mairbäurl H, Metzen E.
    J Cell Sci; 2013 Jun 15; 126(Pt 12):2629-40. PubMed ID: 23606740
    [Abstract] [Full Text] [Related]

  • 10. Insight into the structural basis of pro- and antiapoptotic p53 modulation by ASPP proteins.
    Ahn J, Byeon IL, Byeon CH, Gronenborn AM.
    J Biol Chem; 2009 May 15; 284(20):13812-13822. PubMed ID: 19246451
    [Abstract] [Full Text] [Related]

  • 11. Abnormal expression pattern of the ASPP family of proteins in human non-small cell lung cancer and regulatory functions on apoptosis through p53 by iASPP.
    Li S, Shi G, Yuan H, Zhou T, Zhang Q, Zhu H, Wang X.
    Oncol Rep; 2012 Jul 15; 28(1):133-40. PubMed ID: 22552744
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. ASPP and iASPP: Implication in cancer development and progression.
    Li Y, Ahmad A, Sarkar FH.
    Cell Mol Biol (Noisy-le-grand); 2015 Oct 30; 61(6):2-8. PubMed ID: 26518890
    [Abstract] [Full Text] [Related]

  • 14. Molecular interactions of ASPP1 and ASPP2 with the p53 protein family and the apoptotic promoters PUMA and Bax.
    Patel S, George R, Autore F, Fraternali F, Ladbury JE, Nikolova PV.
    Nucleic Acids Res; 2008 Sep 30; 36(16):5139-51. PubMed ID: 18676979
    [Abstract] [Full Text] [Related]

  • 15. iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human.
    Bergamaschi D, Samuels Y, O'Neil NJ, Trigiante G, Crook T, Hsieh JK, O'Connor DJ, Zhong S, Campargue I, Tomlinson ML, Kuwabara PE, Lu X.
    Nat Genet; 2003 Feb 30; 33(2):162-7. PubMed ID: 12524540
    [Abstract] [Full Text] [Related]

  • 16. Biochemical and structural studies of ASPP proteins reveal differential binding to p53, p63, and p73.
    Robinson RA, Lu X, Jones EY, Siebold C.
    Structure; 2008 Feb 30; 16(2):259-68. PubMed ID: 18275817
    [Abstract] [Full Text] [Related]

  • 17. Flexible Tethering of ASPP Proteins Facilitates PP-1c Catalysis.
    Zhou Y, Millott R, Kim HJ, Peng S, Edwards RA, Skene-Arnold T, Hammel M, Lees-Miller SP, Tainer JA, Holmes CFB, Glover JNM.
    Structure; 2019 Oct 01; 27(10):1485-1496.e4. PubMed ID: 31402222
    [Abstract] [Full Text] [Related]

  • 18. Identification of a novel isoform of iASPP and its interaction with p53.
    Zhang X, Diao S, Rao Q, Xing H, Liu H, Liao X, Wang M, Wang J.
    J Mol Biol; 2007 May 11; 368(4):1162-71. PubMed ID: 17391696
    [Abstract] [Full Text] [Related]

  • 19. Downregulated mRNA expression of ASPP and the hypermethylation of the 5'-untranslated region in cancer cell lines retaining wild-type p53.
    Liu ZJ, Lu X, Zhang Y, Zhong S, Gu SZ, Zhang XB, Yang X, Xin HM.
    FEBS Lett; 2005 Mar 14; 579(7):1587-90. PubMed ID: 15757645
    [Abstract] [Full Text] [Related]

  • 20. p53 target DDA3 binds ASPP2 and inhibits its stimulation on p53-mediated BAX activation.
    Sun WT, Hsieh PC, Chiang ML, Wang MC, Wang FF.
    Biochem Biophys Res Commun; 2008 Nov 14; 376(2):395-8. PubMed ID: 18793611
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.